{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:40:48Z","timestamp":1781606448076,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Micron Foundation Sun Life Singapore"},{"name":"Future Systems and Technology Directorate Singapore Ministry of Defence"},{"name":"National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence Initiative"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus and Vero E6 assay with a quadratic optimization workflow. A starting pool of 12 candidate drugs developed in collaboration with a community of infectious disease clinicians was first narrowed down to a six-drug pool and then interrogated in 50 combination regimens at three dosing levels per drug, representing 729 possible combinations. IDentif.AI-x revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived, and pinpointed a number of clinically actionable drug interactions, which were further reconfirmed in SARS-CoV-2 variants B.1.351 (Beta) and B.1.617.2 (Delta). IDentif.AI-x prioritized promising drug combinations for clinical translation and can be immediately adjusted and re-executed with a new pool of promising therapies in an actionable path towards rapidly optimizing combination therapy following pandemic emergence.<\/jats:p>","DOI":"10.1038\/s41746-022-00627-4","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T06:02:56Z","timestamp":1656568976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-7611","authenticated-orcid":false,"given":"Agata","family":"Blasiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-4437","authenticated-orcid":false,"given":"Anh T. L.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Remus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Hooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Gek Kheng","family":"Seah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-1738","authenticated-orcid":false,"given":"Peter","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De Hoe","family":"Chye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline Pei Chiew","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Tien","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Teng","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-4497","authenticated-orcid":false,"given":"Yee-Joo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5333-1258","authenticated-orcid":false,"given":"David Michael","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Yi Ann","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T. P.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. B.","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Eu-Li","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gek-Yen Gladys","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad En Zuo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Kai-Hua","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"627_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113\u2013119 (2020).","journal-title":"Nature"},{"key":"627_CR2","doi-asserted-by":"publisher","first-page":"e2105815118","DOI":"10.1073\/pnas.2105815118","volume":"118","author":"C Mirabelli","year":"2021","unstructured":"Mirabelli, C. et al. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc. Natl Acad. Sci. 118, e2105815118 (2021).","journal-title":"Proc. Natl Acad. Sci."},{"key":"627_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"KM White","year":"2021","unstructured":"White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371, 926\u2013931 (2021).","journal-title":"Science"},{"key":"627_CR4","doi-asserted-by":"crossref","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, (2020).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"627_CR5","doi-asserted-by":"crossref","unstructured":"Erlanson, D. A. Many small steps towards a COVID-19 drug. Nat. Commun. 11, (2020).","DOI":"10.1038\/s41467-020-18710-3"},{"key":"627_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","volume":"397","author":"PRINCIPLE Trial Collaborative Group et al.","year":"2021","unstructured":"PRINCIPLE Trial Collaborative Group et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 397, 1063\u20131074 (2021).","journal-title":"Lancet"},{"key":"627_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group et al.","year":"2021","unstructured":"RECOVERY Collaborative Group et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med"},{"key":"627_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 384, 795\u2013807 (2021).","journal-title":"N. Engl. J. Med."},{"key":"627_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-018-0069-9","volume":"4","author":"E Tekin","year":"2018","unstructured":"Tekin, E. et al. Prevalence and patterns of higher-order drug interactions in Escherichia coli. npj Syst. Biol. Appl. 4, 31 (2018).","journal-title":"npj Syst. Biol. Appl."},{"key":"627_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43588-020-00007-6","volume":"1","author":"G Galindez","year":"2021","unstructured":"Galindez, G. et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat. Comput. Sci. 1, 33\u201341 (2021).","journal-title":"Nat. Comput. Sci."},{"key":"627_CR11","doi-asserted-by":"publisher","first-page":"e0241543","DOI":"10.1371\/journal.pone.0241543","volume":"15","author":"S Mohapatra","year":"2020","unstructured":"Mohapatra, S. et al. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking. PLoS One 15, e0241543 (2020).","journal-title":"PLoS One"},{"key":"627_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88153-3","volume":"11","author":"A Mongia","year":"2021","unstructured":"Mongia, A., Saha, S. K., Chouzenoux, E. & Majumdar, A. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci. Rep. 11, 9047 (2021).","journal-title":"Sci. Rep."},{"key":"627_CR13","doi-asserted-by":"publisher","first-page":"10442","DOI":"10.1073\/pnas.1606301113","volume":"113","author":"A Zimmer","year":"2016","unstructured":"Zimmer, A., Katzir, I., Dekel, E., Mayo, A. E. & Alon, U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc. Natl Acad. Sci. USA 113, 10442\u201310447 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR14","doi-asserted-by":"publisher","first-page":"2000034","DOI":"10.1002\/adtp.202000034","volume":"3","author":"A Abdulla","year":"2020","unstructured":"Abdulla, A. et al. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. Adv. Ther. 3, 2000034 (2020).","journal-title":"Adv. Ther."},{"key":"627_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-5-88","volume":"5","author":"I Al-Shyoukh","year":"2011","unstructured":"Al-Shyoukh, I. et al. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst. Biol. 5, 88 (2011).","journal-title":"BMC Syst. Biol."},{"key":"627_CR16","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1021\/acsnano.5b00638","volume":"9","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9, 3332\u20133344 (2015).","journal-title":"ACS Nano"},{"key":"627_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/2211068215579612","volume":"20","author":"MB Mohd Abdul Rashid","year":"2015","unstructured":"Mohd Abdul Rashid, M. B. et al. Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas. J. Lab. Autom. 20, 423\u2013437 (2015).","journal-title":"J. Lab. Autom."},{"key":"627_CR18","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1073\/pnas.0800823105","volume":"105","author":"PK Wong","year":"2008","unstructured":"Wong, P. K. et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl Acad. Sci. USA 105, 5105\u20135110 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR19","doi-asserted-by":"publisher","first-page":"e10196","DOI":"10.1002\/btm2.10196","volume":"6","author":"A Blasiak","year":"2021","unstructured":"Blasiak, A. et al. IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. Bioeng. Transl. Med. 6, e10196 (2021).","journal-title":"Bioeng. Transl. Med."},{"key":"627_CR20","doi-asserted-by":"publisher","first-page":"e0215607","DOI":"10.1371\/journal.pone.0215607","volume":"14","author":"DL Clemens","year":"2019","unstructured":"Clemens, D. L. et al. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One 14, e0215607 (2019).","journal-title":"PLoS One"},{"key":"627_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaz3023","volume":"367","author":"D Ho","year":"2020","unstructured":"Ho, D. Artificial intelligence in cancer therapy. Science 367, 982\u2013983 (2020).","journal-title":"Science"},{"key":"627_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","volume":"38","author":"D Ho","year":"2020","unstructured":"Ho, D. et al. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol. 38, 497\u2013518 (2020).","journal-title":"Trends Biotechnol."},{"key":"627_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14183","volume":"8","author":"BY Lee","year":"2017","unstructured":"Lee, B. Y. et al. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat. Commun. 8, 14183 (2017).","journal-title":"Nat. Commun."},{"key":"627_CR24","doi-asserted-by":"publisher","first-page":"1900122","DOI":"10.1002\/adtp.201900122","volume":"3","author":"JJ Lim","year":"2020","unstructured":"Lim, J. J., Goh, J., Rashid, M. B. M. A. & Chow, E. K. Maximizing Efficiency of Artificial Intelligence-Driven Drug Combination Optimization through Minimal Resolution Experimental Design. Adv. Ther. 3, 1900122 (2020).","journal-title":"Adv. Ther."},{"key":"627_CR25","doi-asserted-by":"crossref","unstructured":"Rashid, M. B. M. A. et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci. Transl. Med. 10, (2018).","DOI":"10.1126\/scitranslmed.aan0941"},{"key":"627_CR26","doi-asserted-by":"publisher","first-page":"E2172","DOI":"10.1073\/pnas.1600812113","volume":"113","author":"A Silva","year":"2016","unstructured":"Silva, A. et al. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc. Natl Acad. Sci. USA 113, E2172\u2013E2179 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR27","doi-asserted-by":"crossref","unstructured":"Zarrinpar, A. et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci. Transl. Med. 8, (2016).","DOI":"10.1126\/scitranslmed.aac5954"},{"key":"627_CR28","doi-asserted-by":"crossref","unstructured":"Tan, B. K. J. et al. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Front. Digit. Heal. 3, (2021).","DOI":"10.3389\/fdgth.2021.635524"},{"key":"627_CR29","doi-asserted-by":"publisher","first-page":"1900114","DOI":"10.1002\/adtp.201900114","volume":"3","author":"Y Shen","year":"2020","unstructured":"Shen, Y. et al. Harnessing Artificial Intelligence to Optimize Long-Term Maintenance Dosing for Antiretroviral-Naive Adults with HIV-1 Infection. Adv. Ther. 3, 1900114 (2020).","journal-title":"Adv. Ther."},{"key":"627_CR30","doi-asserted-by":"publisher","first-page":"1800104","DOI":"10.1002\/adtp.201800104","volume":"1","author":"AJ Pantuck","year":"2018","unstructured":"Pantuck, A. J. et al. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform. Adv. Ther. 1, 1800104 (2018).","journal-title":"Adv. Ther."},{"key":"627_CR31","doi-asserted-by":"crossref","unstructured":"Kee, T. et al. Harnessing CURATE.AI as a Digital Therapeutics Platform by Identifying N-of-1 Learning Trajectory Profiles. Adv. Ther. 2, (2019).","DOI":"10.1002\/adtp.201900023"},{"key":"627_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0276-7","volume":"10","author":"S de Mel","year":"2020","unstructured":"de Mel, S. et al. Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer J. 10, 9 (2020).","journal-title":"Blood Cancer J."},{"key":"627_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2472630319890316","volume":"25","author":"A Blasiak","year":"2020","unstructured":"Blasiak, A., Khong, J. & Kee, T. CURATE.AI: Optimizing Personalized Medicine with. Artif. Intell. SLAS Technol. 25, 95\u2013105 (2020).","journal-title":"Artif. Intell. SLAS Technol."},{"key":"627_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 \u2014 Final Report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"627_CR35","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID -19 patients. EMBO Mol. Med. 12, e12697 (2020).","journal-title":"EMBO Mol. Med."},{"key":"627_CR36","doi-asserted-by":"publisher","first-page":"12256","DOI":"10.1021\/acs.jmedchem.0c00502","volume":"63","author":"S Xiu","year":"2020","unstructured":"Xiu, S. et al. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. J. Med. Chem. 63, 12256\u201312274 (2020).","journal-title":"J. Med. Chem."},{"key":"627_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1126\/science.abg5827","volume":"373","author":"N Drayman","year":"2021","unstructured":"Drayman, N. et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science 373, 931\u2013936 (2021).","journal-title":"Science"},{"key":"627_CR38","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","volume":"383","author":"JD Goldman","year":"2020","unstructured":"Goldman, J. D. et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med. 383, 1827\u20131837 (2020).","journal-title":"N. Engl. J. Med."},{"key":"627_CR39","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"627_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","volume":"6","author":"RM Cox","year":"2021","unstructured":"Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 6, 11\u201318 (2021).","journal-title":"Nat. Microbiol."},{"key":"627_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.09.014","volume":"141","author":"K El Bairi","year":"2020","unstructured":"El Bairi, K. et al. Repurposing anticancer drugs for the management of COVID-19. Eur. J. Cancer 141, 40\u201361 (2020).","journal-title":"Eur. J. Cancer"},{"key":"627_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijsu.2020.10.018","volume":"84","author":"CV Haritha","year":"2020","unstructured":"Haritha, C. V., Sharun, K. & Jose, B. Ebselen, a new candidate therapeutic against SARS-CoV-2. Int. J. Surg. 84, 53\u201356 (2020).","journal-title":"Int. J. Surg."},{"key":"627_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","volume":"28","author":"DW Kneller","year":"2020","unstructured":"Kneller, D. W. et al. Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals. Structure 28, 1313\u20131320 (2020). e3.","journal-title":"Structure"},{"key":"627_CR44","doi-asserted-by":"publisher","first-page":"110180","DOI":"10.1016\/j.mehy.2020.110180","volume":"144","author":"B Lovetrue","year":"2020","unstructured":"Lovetrue, B. The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients. Med. Hypotheses 144, 110180 (2020).","journal-title":"Med. Hypotheses"},{"key":"627_CR45","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J. Am. Med. Assoc. 323, 1824\u20131836 (2020).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"627_CR46","doi-asserted-by":"publisher","unstructured":"Khoo, S. H. et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J. Antimicrob. Chemother. (2021). https:\/\/doi.org\/10.1093\/jac\/dkab318","DOI":"10.1093\/jac\/dkab318"},{"key":"627_CR47","doi-asserted-by":"crossref","unstructured":"Painter, W. P. et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 65, (2021).","DOI":"10.1128\/AAC.02428-20"},{"key":"627_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22580-8","volume":"12","author":"K Rosenke","year":"2021","unstructured":"Rosenke, K. et al. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat. Commun. 12, 2295 (2021).","journal-title":"Nat. Commun."},{"key":"627_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"627_CR50","doi-asserted-by":"publisher","unstructured":"Fischer, W. A. 2nd et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 14, eabl7430 (2022). https:\/\/doi.org\/10.1126\/scitranslmed.abl7430.","DOI":"10.1126\/scitranslmed.abl7430"},{"key":"627_CR51","doi-asserted-by":"publisher","first-page":"n2422","DOI":"10.1136\/bmj.n2422","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ 375, n2422 (2021).","journal-title":"BMJ"},{"key":"627_CR52","unstructured":"Medicines and Healthcare products Regulatory Agency. First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA - GOV.UK. https:\/\/www.gov.uk\/government\/news\/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra. (Accessed: 11th November 2021)"},{"key":"627_CR53","unstructured":"Merck & Co. Inc. Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19. https:\/\/www.merck.com\/news\/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19\/ (Accessed: 1st December 2021)"},{"key":"627_CR54","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. Food and Drug Administration 1 (2021). Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. (Accessed: 15th March 2022)"},{"key":"627_CR55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHO Solidarity Trial Consortium.","year":"2021","unstructured":"WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results. N. Engl. J. Med. 384, 497\u2013511 (2021).","journal-title":"N. Engl. J. Med."},{"key":"627_CR56","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.7326\/M21-0653","volume":"174","author":"A Barratt-Due","year":"2021","unstructured":"Barratt-Due, A. et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in covid-19: A randomized trial. Ann. Intern. Med. 174, 1261\u20131269 (2021).","journal-title":"Ann. Intern. Med."},{"key":"627_CR57","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","volume":"9","author":"J Aman","year":"2021","unstructured":"Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir. Med. 9, 957\u2013968 (2021).","journal-title":"Lancet Respir. Med."},{"key":"627_CR58","doi-asserted-by":"crossref","unstructured":"Schultz, D. C. et al. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature 1\u20139 (2022).","DOI":"10.1101\/2021.06.24.449811"},{"key":"627_CR59","doi-asserted-by":"publisher","first-page":"100539","DOI":"10.1016\/j.eclinm.2020.100539","volume":"27","author":"J Mart\u00ednez-Sanz","year":"2020","unstructured":"Mart\u00ednez-Sanz, J., P\u00e9rez-Molina, J. A., Moreno, S., Zamora, J. & Serrano-Villar, S. Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey. EClinicalMedicine 27, 100539 (2020).","journal-title":"EClinicalMedicine"},{"key":"627_CR60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.7326\/M20-8179","volume":"174","author":"JP Metlay","year":"2021","unstructured":"Metlay, J. P. & Armstrong, K. A. Clinical Decision Making During the COVID-19 Pandemic. Ann. Intern. Med. 174, 691\u2013693 (2021).","journal-title":"Ann. Intern. Med."},{"key":"627_CR61","unstructured":"Bhimraj, A. et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2021, (2020)."},{"key":"627_CR62","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1016\/S2214-109X(21)00251-5","volume":"9","author":"GW Strohbehn","year":"2021","unstructured":"Strohbehn, G. W., Parker, W. F., Reid, P. D. & Gellad, W. F. Socially optimal pandemic drug dosing. Lancet Glob. Heal 9, e1049\u2013e1050 (2021).","journal-title":"Lancet Glob. Heal"},{"key":"627_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400\u2013402 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"627_CR64","doi-asserted-by":"crossref","unstructured":"Gysi, D. M. et al. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc. Natl. Acad. Sci. USA 118, (2021).","DOI":"10.1073\/pnas.2025581118"},{"key":"627_CR65","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"BR Beck","year":"2020","unstructured":"Beck, B. R., Shin, B., Choi, Y., Park, S. & Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784\u2013790 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"627_CR66","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2020.3204","volume":"323","author":"BE Young","year":"2020","unstructured":"Young, B. E. et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 323, 1488\u20131494 (2020).","journal-title":"JAMA"},{"key":"627_CR67","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/cpt.1909","volume":"108","author":"U Arshad","year":"2020","unstructured":"Arshad, U. et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin. Pharmacol. Ther. 108, 775\u2013790 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"627_CR68","doi-asserted-by":"publisher","unstructured":"Xu, H., Jaynes, J. & Ding, X. Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration. Stat Sin 269\u2013289, https:\/\/doi.org\/10.5705\/ss.2012.210. (2014).","DOI":"10.5705\/ss.2012.210."},{"key":"627_CR69","first-page":"49","volume":"33","author":"I Farrance","year":"2012","unstructured":"Farrance, I. & Frenkel, R. Uncertainty of Measurement: A Review of the Rules for Calculating Uncertainty Components through Functional Relationships. Clin. Biochem Rev. 33, 49\u201375 (2012).","journal-title":"Clin. Biochem Rev."},{"key":"627_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein, R. L., Schirm, A. L. & Lazar, N. A. Moving to a World Beyond \u201cp\u2009<\u20090.05\u201d. Am. Stat. 73, 1\u201319 (2019).","journal-title":"Am. Stat."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00627-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00627-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00627-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:04:22Z","timestamp":1669345462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00627-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00627-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.23.21259321","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B., E.K-.H.C., and D.H. are co-inventors or previously filed pending patents on artificial intelligence-based therapy development. E.K.-H.C., and D.H. are shareholders of KYAN Therapeutics, which has licensed intellectual property pertaining to AI-based oncology drug development. The findings from this study are being made available for public benefit, and no intellectual property rights arising from the work reported here are being pursued. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}